Topic:

Sales and Marketing

Latest Headlines

Latest Headlines

Novo Nordisk picks diabetes-ridden Mexico for first Ryzodeg launch

Earlier this year, Novo Nordisk said it would target Mexico as its next market for an obesity-fighting formula of liraglutide, sold for diabetes as Victoza. Now, the company has picked Mexico for its first launch of Ryzodeg, a brand-new combo diabetes treatment.

Novartis ready to start its engines for 'most exciting launch' in company history

Pharma executives tend to be circumspect when they talk about drug launches. After all, we've seen CEOs predict big things, only to be assaulted later by a pitchfork-toting mob. Plus, there's the don't-jinx-it school of thought. Apparently, neither worry applies to Novartis pharma chief David Epstein--at least when he's talking about the company's new heart failure drug LCZ696.

FDA says Aegerion has satisfied its demands over chatty CEO

Comments by Marc Beer, CEO of Aegerion Pharmaceuticals, got the company slapped with an FDA warning letter for exaggerating the benefits of its cholesterol-lowering drug Juxtapid during a television appearance on CNBC's "Fast Money" program. Beer had nothing to say Wednesday when the company announced the FDA had closed the matter out, satisfied with the "corrective actions" the company had taken.

PhRMA jumps into Integrilin off-label case, free-speech arguments at the ready

Since a U.S. circuit court decided the First Amendment protected a pharma sales rep from off-label marketing charges, the free-speech arguments have multiplied in cases across the country, testing that Second Circuit decision in other regions.

Celebrity pitch-folks may not be worth the money, study finds

Celebrities are making more and more appearances in pharma's DTC advertising. But do they help meds score with patients the same way they help sell consumer goods?

Merck taps celeb chef to deliver diabetes message to Hispanics

Merck's America's Diabetes Challenge: Get to Your Goals campaign is aimed at persuading patients to do what it takes to keep their blood sugar in check. Now, Merck is launching a similar campaign aimed at the Hispanic community, which is disproportionately affected by the disease.

Price could be key for Sanofi's new Gaucher pill as it sets out against IV rivals

More than a couple of markets have been shaken up lately by new competition in oral form. And now, Sanofi's Genzyme is wondering if it can't make a splash of its own with Cerdelga, its newly approved pill for Gaucher disease.

Big Pharma doesn't win the margin stakes. That's Jazz, Celgene, Regeneron and Alexion

Margins, margins, margins. That's an inevitable mantra among top investors and analysts. Just ask Novartis CEO Joe Jimenez, who's pledged big improvements in the Swiss drugmaker's spread. Or Eli Lilly CFO Derica Rice, who's had to explain why his company can promise to maintain margins as its sales spiral downward.

The irrational rationale for cancer drug prices, with Novartis' Zykadia as exhibit A

Why do cancer drugs cost so much? We all know the stock answer--because companies need to recoup their development costs. Whether we believe it is something else, as Peter Bach of the Center for Health Policy and Outcomes writes in Forbes.

Sovaldi payer pushback hurting access for opioid treatment patients

Payers have been getting creative as they look for ways to minimize the damage of Gilead's $84,000-per-treatment-course hep C wonder drug Sovaldi to their budgets and bottom lines. Now, some are balking at covering the med for those enrolled in opioid treatment programs.